Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

9431 ARTÍCULOS , VIENDO DEL 5416 AL 5430

PDD-5S: A useful screening tool for Parkinson's disease dementia

Lee WJ, Wu SL, Li JY, Chen CC, Lin JJ, Peng GS, Lin TK, Wang SJ, Chen RS, Yang YH, Tsai CH, Hsu JL, Liao YC, Chen SP, Fuh JL.

Parkinsonism Relat Disord. 2016 Apr;25:85-90. doi: 10.1016/j.parkreldis.2016.02.001. Epub 2016 Feb 3.

Parkinson's disease-related fatigue: A case definition and recommendations for clinical research

Kluger BM, Herlofson K, Chou KL, Lou JS, Goetz CG, Lang AE, Weintraub D, Friedman J.

Mov Disord. 2016 May;31(5):625-31. doi: 10.1002/mds.26511. Epub 2016 Feb 16.

Imaging synucleinopathies

Brooks DJ, Tambasco N.

Mov Disord. 2016 Jun;31(6):814-29. doi: 10.1002/mds.26547. Epub 2016 Feb 16.

The pedunculopontine tegmental nucleus-A functional hypothesis from the comparative literature

Gut NK, Winn P.

Mov Disord. 2016 May;31(5):615-24. doi: 10.1002/mds.26556. Epub 2016 Feb 16.

Subthalamic stimulation may inhibit the beneficial effects of levodopa on akinesia and gait

Fleury V, Pollak P, Gere J, Tommasi G, Romito L, Combescure C, Bardinet E, Chabardes S, Momjian S, Krainik A, Burkhard P, Yelnik J, Krack P.

Mov Disord. 2016 Sep;31(9):1389-97. doi: 10.1002/mds.26545. Epub 2016 Feb 17.

Neuro-QoL health-related quality of life measurement system: Validation in Parkinson's disease

Nowinski CJ, Siderowf A, Simuni T, Wortman C, Moy C, Cella D.

Mov Disord. 2016 May;31(5):725-33. doi: 10.1002/mds.26546. Epub 2016 Feb 26.

Lysosomal Dysfunction and α-Synuclein Aggregation in Parkinson's Disease: Diagnostic Links

Moors T, Paciotti S, Chiasserini D, Calabresi P, Parnetti L, Beccari T, van de Berg WD.

Mov Disord. 2016 Jun;31(6):791-801. doi: 10.1002/mds.26562. Epub 2016 Feb 29.

Targeting α-synuclein: Therapeutic options

Dehay B, Decressac M, Bourdenx M, Guadagnino I, Fernagut PO, Tamburrino A, Bassil F, Meissner WG, Bezard E.

Mov Disord. 2016 Jun;31(6):882-8. doi: 10.1002/mds.26568. Epub 2016 Mar 1.

Current status and future challenges of brain imaging with (18)F-DOPA PET for movement disorders

Calabria FF, Calabria E, Gangemi V, Cascini GL.

Hell J Nucl Med. 2016 Jan-Apr;19(1):33-41. doi: 10.1967/s002449910335. Epub 2016 Mar 1.

The mPower study, Parkinson disease mobile data collected using ResearchKit

Bot BM, Suver C, Neto EC, Kellen M, Klein A, Bare C, Doerr M, Pratap A, Wilbanks J, Dorsey ER, Friend SH, Trister AD.

Sci Data. 2016 Mar 3;3:160011. doi: 10.1038/sdata.2016.11.

Treadmill training for patients with Parkinson Disease. An abridged version of a Cochrane Review

Mehrholz J, Kugler J, Storch A, Pohl M, Hirsch K, Elsner B.

Eur J Phys Rehabil Med. 2016 Oct;52(5):704-713. Epub 2016 Mar 4.

Measurement instruments to assess posture, gait, and balance in Parkinson's disease: Critique and recommendations

Bloem BR, Marinus J, Almeida Q, Dibble L, Nieuwboer A, Post B, Ruzicka E, Goetz C, Stebbins G, Martinez-Martin P, Schrag A; Movement Disorders Society Rating Scales Committee.

Mov Disord. 2016 Sep;31(9):1342-55. doi: 10.1002/mds.26572. Epub 2016 Mar 4.

Glycation in Parkinson's disease and Alzheimer's disease

Vicente Miranda H, El-Agnaf OM, Outeiro TF.

Mov Disord. 2016 Jun;31(6):782-90. doi: 10.1002/mds.26566. Epub 2016 Mar 4.

Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy

Stamelou M, Schöpe J, Wagenpfeil S, Del Ser T, Bang J, Lobach IY, Luong P, Respondek G, Oertel WH, Boxer A, Höglinger GU; AL-108-231 Investigators, Tauros Investigators, and MDS-Endorsed PSP Study Group.

Mov Disord. 2016 May;31(5):742-7. doi: 10.1002/mds.26580. Epub 2016 Mar 7.

Factors influencing the outcome of deep brain stimulation: Placebo, nocebo, lessebo, and lesion effects

Mestre TA, Lang AE, Okun MS.

Mov Disord. 2016 Mar;31(3):290-6. doi: 10.1002/mds.26500.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias